AMRI shutters R&D site, moving jobs to Singapore

CRO AMRI ($AMRI) is closing up its R&D shop in Bothell, WA, and shipping the site's biology capabilities to its drug discovery operation in Singapore. The Bothell plant employs 24 people, AMRI said in a statement, and the cost-cutting measure is designed to "address and anticipate changes in the marketplace," according to the company. AMRI expects to shut down the plant by the end of the first quarter, and it will transfer Bothell's analytic capabilities to its headquarters in Albany, NY. Story

Suggested Articles

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.

Raxone is currently in a phase 3 study on DMD patients who are taking glucocorticoids.

The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.